Proton Calibration Technologies

We are on the front lines of developing the 5th medical imaging modality – proton Computed Tomography (pCT). Each new modality – X-ray/CT, MRI, Ultrasound, and PET – has had a profound impact on medical care by providing improved visualization of internal anatomy and processes. pCT will do this again by providing 3D images of patient anatomy using protons. As a result, it will greatly improve the treatment of solid tumors and cardiac arrhythmias. Other new applications for proton therapy are sure to follow with the adoption of pCT.

Our mission at Proton Calibration Technologies (PCT) is to bring pCT into healthcare clinical practice. For more than 20 years the proton therapy community has sought to invent pCT. With pCT the “range uncertainty issue” of proton beam therapy (PBT) will be eliminated. As a result, proton therapy centers can begin treating with the Bragg Peak directly rather than using its penumbra.

Knowing where the Bragg Peak will “cut” in the patient will enable hypofractionation – meaning the delivery of proton therapy in fewer sessions, or fractions – each of higher dose. This will enable more patients to have access to PBT and shorten treatment time from from six to eight weeks to just one week.

Knowing precisely where the Bragg Peak will cut will also result in the switch from catheterization for cardiac ablation to proton ablation. pCT will enable cardiac ablation to become a 30-minute outpatient procedure with no anesthesia; the patient will be able to stand up and walk out the same day. It should be noted that pCT will also become an important tool in material science.

Proton Calibration Technologies logo


Proton Calibration Technologies
986 N. Cedar Cove Road
Hartselle, AL 35640


Paul Mulqueen, PhD


Paul is an innovative executive with extensive global medical engineering and business development experience. Throughout his career, he has successfully managed geographically distributed teams and exceeded P&L targets. As the CEO of Proton Calibration Technologies, Paul invented the enabling algorithm and obtained the seed funding to help bring proton computed tomography to the market.

Prior to his work with PTC, Paul created the vision to commercialize proton ion and carbon ion cancer therapy systems at another venture firm. While there, he negotiated the agreements required to establish the worldwide network needed for a ground up approach to the design of the ion therapy product. Paul also worked with merchant banks and individual investors to raise the required funds, and developed the cost model for the development, manufacture, installation, and field service of the ion therapy system.

Paul has also served as the Vice President of Design & Test Engineering at a Fortune 500 Company. During his time there, Paul established a medical engineering design center. The department had its own P&L and grew through client revenue rather than corporate investment. Project revenues ranged from $200K to $17M.


Stephen Sledge

VP of Business Development

Stephen has over two decades of experience in the medical device industry, specifically with the commercial side in proton therapy and radiation therapy, serving in key roles with responsibilities including business development, upstream/downstream marketing and product management – including work with Siemens, Elekta, IBA, ProTom and Hitachi. Stephen brings a broad skill set of business and technical competencies as well as depth to the Proton Calibration Technologies team with his background in physics and electrical engineering.

Advisory Board

Dimitri D., PhD
Scientific Advisor, Physicist

Aashish Bhatt, MD
Medical Advisor, Radiation Oncologist

Evgene Galyaev, PhD
Physicist Detector Advisor

Contact Us

For Partnership &
Investment Opportunities

Together, we can take the treatment of cancer and cardiac arrhythmias to the next level.